Genomic Health, Inc. (GHDX) Director Sells $2,168,365.31 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) Director Henry J. Fuchs sold 26,479 shares of Genomic Health stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of $81.89, for a total value of $2,168,365.31. Following the transaction, the director now owns 26,332 shares of the company’s stock, valued at approximately $2,156,327.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Genomic Health stock opened at $75.97 on Friday. Genomic Health, Inc. has a twelve month low of $30.04 and a twelve month high of $92.18. The stock has a market capitalization of $2.75 billion, a P/E ratio of 72.35 and a beta of 0.88.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.02. Genomic Health had a return on equity of 17.73% and a net margin of 6.52%. The firm had revenue of $104.56 million during the quarter, compared to analyst estimates of $101.55 million. During the same quarter in the previous year, the business earned $0.05 EPS. Genomic Health’s revenue for the quarter was up 22.0% compared to the same quarter last year. As a group, research analysts forecast that Genomic Health, Inc. will post 1.49 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the stock. Royce & Associates LP boosted its holdings in Genomic Health by 22.8% in the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after buying an additional 273 shares during the last quarter. Advisor Group Inc. boosted its holdings in Genomic Health by 34.9% in the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after buying an additional 516 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Genomic Health in the 3rd quarter worth about $171,000. Quantamental Technologies LLC acquired a new stake in Genomic Health in the 4th quarter worth about $180,000. Finally, Trexquant Investment LP acquired a new stake in Genomic Health in the 3rd quarter worth about $202,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.

GHDX has been the subject of a number of recent research reports. Canaccord Genuity reiterated a “buy” rating and set a $82.00 price objective (up previously from $70.00) on shares of Genomic Health in a research note on Wednesday, November 7th. BidaskClub lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday. ValuEngine lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 11th. Zacks Investment Research restated a “hold” rating on shares of Genomic Health in a research note on Tuesday, November 13th. Finally, CIBC assumed coverage on Genomic Health in a research note on Wednesday, December 19th. They issued a “market perform” rating for the company. Nine analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $63.13.

ILLEGAL ACTIVITY NOTICE: “Genomic Health, Inc. (GHDX) Director Sells $2,168,365.31 in Stock” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2019/03/01/genomic-health-inc-ghdx-director-sells-2168365-31-in-stock.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Read More: How to execute a trade ex-dividend strategy?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply